Your browser doesn't support javascript.
loading
A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.
Pacini, Clare; Duncan, Emma; Gonçalves, Emanuel; Gilbert, James; Bhosle, Shriram; Horswell, Stuart; Karakoc, Emre; Lightfoot, Howard; Curry, Ed; Muyas, Francesc; Bouaboula, Monsif; Pedamallu, Chandra Sekhar; Cortes-Ciriano, Isidro; Behan, Fiona M; Zalmas, Lykourgos-Panagiotis; Barthorpe, Andrew; Francies, Hayley; Rowley, Steve; Pollard, Jack; Beltrao, Pedro; Parts, Leopold; Iorio, Francesco; Garnett, Mathew J.
Affiliation
  • Pacini C; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Duncan E; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Gonçalves E; Instituto Superior Técnico (IST), Universidade de Lisboa, 1049-001 Lisboa, Portugal; INESC-ID, 1000-029 Lisboa, Portugal.
  • Gilbert J; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Bhosle S; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Horswell S; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Karakoc E; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Lightfoot H; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Curry E; Genome Biology, Genomic Sciences, GSK, Stevenage, UK.
  • Muyas F; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge CB10 1SD, UK.
  • Bouaboula M; Sanofi Research and Development, Cambridge, MA, USA.
  • Pedamallu CS; Sanofi Research and Development, Cambridge, MA, USA.
  • Cortes-Ciriano I; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge CB10 1SD, UK.
  • Behan FM; Genome Biology, Genomic Sciences, GSK, Stevenage, UK.
  • Zalmas LP; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Barthorpe A; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Francies H; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Genome Biology, Genomic Sciences, GSK, Stevenage, UK.
  • Rowley S; Sanofi Research and Development, Cambridge, MA, USA.
  • Pollard J; Sanofi Research and Development, Cambridge, MA, USA.
  • Beltrao P; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge CB10 1SD, UK.
  • Parts L; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • Iorio F; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Human Technopole, V.le Rita Levi-Montalcini, 1, 20157 Milano, Italy. Electronic address: francesco.iorio@fht.org.
  • Garnett MJ; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK; Open Targets, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK. Electronic address: mg12@sanger.ac.uk.
Cancer Cell ; 42(2): 301-316.e9, 2024 02 12.
Article in En | MEDLINE | ID: mdl-38215750
ABSTRACT
Genetic screens in cancer cell lines inform gene function and drug discovery. More comprehensive screen datasets with multi-omics data are needed to enhance opportunities to functionally map genetic vulnerabilities. Here, we construct a second-generation map of cancer dependencies by annotating 930 cancer cell lines with multi-omic data and analyze relationships between molecular markers and cancer dependencies derived from CRISPR-Cas9 screens. We identify dependency-associated gene expression markers beyond driver genes, and observe many gene addiction relationships driven by gain of function rather than synthetic lethal effects. By combining clinically informed dependency-marker associations with protein-protein interaction networks, we identify 370 anti-cancer priority targets for 27 cancer types, many of which have network-based evidence of a functional link with a marker in a cancer type. Mapping these targets to sequenced tumor cohorts identifies tractable targets in different cancer types. This target prioritization map enhances understanding of gene dependencies and identifies candidate anti-cancer targets for drug development.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Testing / Neoplasms Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Testing / Neoplasms Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: United kingdom